您的购物车当前为空
CT52923是一种选择性、口服活性的血小板衍生生长因子受体(PDGFR)拮抗剂,以ATP竞争性抑制作用功能。它适用于多种病理性疾病的研究,包括动脉粥样硬化、肾小球肾炎、肝硬化、肺纤维化和癌症。


为众多的药物研发团队赋能,
让新药发现更简单!
CT52923是一种选择性、口服活性的血小板衍生生长因子受体(PDGFR)拮抗剂,以ATP竞争性抑制作用功能。它适用于多种病理性疾病的研究,包括动脉粥样硬化、肾小球肾炎、肝硬化、肺纤维化和癌症。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 108 | In Stock | |
| 5 mg | ¥ 268 | In Stock | |
| 10 mg | ¥ 418 | In Stock | |
| 25 mg | ¥ 833 | In Stock | |
| 50 mg | ¥ 1,330 | In Stock | |
| 100 mg | ¥ 1,930 | In Stock | |
| 200 mg | ¥ 2,830 | In Stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 316 | In Stock |
CT52923 相关产品
| 产品描述 | CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer. |
| 体外活性 | CT52923通过抑制PDGFRs和干细胞因子受体,其IC50值介于100至200 nM之间。在0.01-30 μM浓度和24小时作用下,CT52923能有效阻断由血小板衍生生长因子诱导的平滑肌细胞迁移或成纤维细胞增殖,相应的IC50值分别为64和280 nM [1]。 |
| 体内活性 | CT52923(口服;5,15,30和50 mg/kg;每日两次)在大鼠颈动脉损伤后显著抑制新内膜形成[1]。 |
| 分子量 | 467.54 |
| 分子式 | C23H25N5O4S |
| CAS No. | 205256-55-9 |
| Smiles | COc1cc2ncnc(N3CCN(CC3)C(=S)NCc3ccc4OCOc4c3)c2cc1OC |
| 密度 | 1.370 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 60 mg/mL (128.33 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容